Should an antidepressant be added for a patient whose mood instability is being controlled with cariprazine (Vraylar)?

Do Not Add an Antidepressant at This Time

Since cariprazine (Vraylar) is already providing mood stabilization and is FDA-approved for adjunctive treatment of major depressive disorder, you should continue optimizing the current cariprazine monotherapy rather than adding an antidepressant. 1

Clinical Reasoning

Why Cariprazine Alone May Be Sufficient

Cariprazine has demonstrated efficacy as adjunctive therapy to antidepressants in major depressive disorder 2, but more importantly for your patient, it is approved for treating bipolar depression and mood stabilization 1. The fact that mood stabilization is already occurring suggests the medication is working as intended.

Recent evidence shows:

• Cariprazine 1.5 mg/day significantly reduced depressive symptoms (MADRS score improvement of -14.1 vs -11.5 for placebo) when used adjunctively 2
• The drug provides clinically meaningful improvements across individual depressive symptoms, not just overall mood 3
• It has a neutral metabolic profile with minimal weight gain (<1 kg) 4

The Bipolar Consideration - Critical Decision Point

If this patient has any bipolar features (even subsyndromal), adding an antidepressant could be harmful. The guidelines explicitly warn that antidepressants in bipolar disorder can:

• Destabilize mood 5
• Precipitate manic episodes 5
• Cause disinhibition 5

The guideline states: "Antidepressants may be useful adjuncts for depression as long as the patient is also taking at least one mood stabilizer" 5. However, cariprazine functions as both an atypical antipsychotic AND has mood-stabilizing properties, making it the appropriate foundation.

Practical Algorithm for Your Decision

Before adding an antidepressant, assess:

1. Duration of current cariprazine trial: Has the patient been on an adequate dose for 6-8 weeks? 2

   • If <6 weeks: Continue current regimen
   • If ≥6 weeks with partial response: Consider dose optimization first

2. Current cariprazine dose:

   • Therapeutic range is 1.5-3 mg/day for depression 1, 2
   • The 1.5 mg dose showed superior efficacy to 3 mg in one major trial 2
   • Optimize within this range before adding agents

3. Bipolar spectrum features (even subtle):

   • History of hypomania, irritability, racing thoughts, decreased need for sleep
   • Family history of bipolar disorder
   • Previous antidepressant-induced activation or mood switching
   • If ANY of these present: Do NOT add antidepressant 5, 6

4. Residual depressive symptoms:

   • If mood is stable but depression persists after adequate cariprazine trial, then consider augmentation
   • Recent evidence supports cariprazine as the augmenting agent to antidepressants, not the reverse 7, 8

Common Pitfalls to Avoid

• Premature polypharmacy: The guideline warns to "avoid unnecessary polypharmacy" 5. Give cariprazine adequate time and dose optimization first.

• Unrecognized bipolarity: "Hidden (subsyndromal or subthreshold) bipolarity is one of the most frequent causes of treatment resistance" 6. The fact that cariprazine is helping with mood stabilization raises suspicion for bipolar spectrum features.

• Antidepressant-induced destabilization: If bipolar features exist, adding an SSRI could unmask the disorder or cause disinhibition 5

Monitoring While Continuing Current Therapy

Watch for these adverse effects with cariprazine (most common: akathisia, nausea, insomnia) 1, 4:

• Akathisia occurs in a dose-dependent manner 4
• Most adverse events are mild-to-moderate 4
• Discontinuation rate due to adverse events is only 4.3% 4

If you ultimately decide an antidepressant is necessary (after 6-8 weeks of optimized cariprazine with persistent depression and NO bipolar features), the combination would follow the guideline principle of having a mood stabilizer/atypical antipsychotic on board first 5. But this should be a last resort, not the next step.